Global Natural Killer Cell Therapeutics Market Growth (Status and Outlook) 2024-2030

Global Natural Killer Cell Therapeutics Market Growth (Status and Outlook) 2024-2030

NK cells, a type of immune cell, have received a lot of attention for their natural capacity to recognize and kill malignant cells. Advances in understanding NK cell biology and its interactions with Cancer have resulted in the development of new medicines that harness the potential of these cells. With the success of CAR-NK cell therapies in preclinical and early clinical trials, there is growing optimism about the ability of NK cell-based immunotherapies to treat a wide spectrum of cancer types.

The global Natural Killer Cell Therapeutics market size is projected to grow from US$ 184 million in 2024 to US$ 1418 million in 2030; it is expected to grow at a CAGR of 40.6% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Natural Killer Cell Therapeutics Industry Forecast” looks at past sales and reviews total world Natural Killer Cell Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Natural Killer Cell Therapeutics sales for 2023 through 2029. With Natural Killer Cell Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Natural Killer Cell Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Natural Killer Cell Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Natural Killer Cell Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Natural Killer Cell Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Natural Killer Cell Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Natural Killer Cell Therapeutics.

Another important driver for the NK Cell Therapeutics Market is the rising global prevalence of Cancer, combined with ongoing unmet medical needs in cancer treatment. Despite advances in traditional medicines such as chemotherapy and targeted therapy, certain malignancies continue to be refractory or develop treatment resistance. This highlights the critical need for novel therapeutic approaches, such as NK cell-based immunotherapy, which has the potential to improve efficacy while reducing adverse effects. As the cancer burden grows, fuelled by factors such as aging populations and lifestyle changes, there is an increasing need to discover effective medicines, driving demand for NK cell therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Natural Killer Cell Therapeutics market by product type, application, key players and key regions and countries.

Segmentation by Type:
NK Cell Therapies
NK Cell Directed Antibodies

Segmentation by Application:
Research & Academic Institutes
Hospitals
Specialty Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
NK Cell Therapies
NK Cell Directed Antibodies

Segmentation by Application:
Research & Academic Institutes
Hospitals
Specialty Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck KGaA
Bristol-Myers Squibb Company
Glycostem
Sanofi
Cytovia Therapeutics
ImmunityBio, Inc.
Biohaven Pharmaceuticals
Fate Therapeutics
EMERcell
Phio Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.